Dr. Peter Heinrich is a co-founder of MediGene AG and has been chairman of the Executive Board of the company since 1995. He was previously in charge of developing the biotechnology division at Wacker Chemie. In his seven years with Wacker he held various positions in research and management, including responsibility for cooperation with Japanese and U.S. biotech corporations. After studying biology and chemistry at the University of Munich and receiving a PhD in biochemistry he worked as a scientist at Harvard University.
Dr. Peter Heinrich is President of Emerging Biopharmaceutical Enterprises (EBE), a specialized group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels. He is a co-founder and chairman of the Association of German Biotechnology Corporations (VBU), a board member of the Society for Chemical Engineering and Biotechnology e. V. (DECHEMA), a member of the board of governors of Bayern Innovativ GmbH and a mentor of the Bayerische Eliteakademie.
